Skip to content
GLP-1 Decoder

Saxenda for PCOS: Evidence, Eligibility, Coverage

Saxenda is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for weight loss. Some doctors prescribe it when one of those uses also applies. In SCALE Obesity and Prediabetes, people on Saxenda lost 7.4% of body weight on average, vs 3% on placebo.

Active ingredient
liraglutide
How it is taken
daily injection
Approved for
Weight loss
Best result (SCALE Obesity and Prediabetes)
7.4% weight loss

Saxenda in brief

How long it remains in the body
100%50%25%0%013 h26 h39 h2.2 d2.7 d50%25%12.5%time after the dose

The half-life is about 13 hours: after 13 h half is gone, and after five half-lives (2.7 d) about 3% is left.

Main trial: weight lost
Saxenda (SCALE Obesity and Prediabetes)7.4%Placebo3%

SCALE Obesity and Prediabetes, 56 weeks: body weight fell 7.4%, while placebo showed 3%.

Source: FDA label from DailyMed.

Who qualifies?

Who qualifies for Saxenda
Who sets the ruleWho qualifies
FDA labelWith diet and activity, it helps adults and children 12 and older who have obesity (over 60 kg) lose weight and keep it off long term. It also helps adults who have overweight plus a condition linked to weight.
Typical commercial plan (Aetna policy)BMI 30 or higher
Typical commercial plan (Aetna policy)BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)a diet and activity program runs for 6 months first

Sources: FDA label (DailyMed), aetna.com.

PCOS trial results

None of these trials enrolled only polycystic ovary syndrome (PCOS); the people studied were all participants were adults who had obesity or overweight and did not have type 2 diabetes.

Saxenda trials in polycystic ovary syndrome (PCOS)
TrialMedicineWho took partLengthPeopleMain resultComparison
SCALE Obesity and Prediabetes SaxendaAll participants were adults who had obesity or overweight and did not have type 2 diabetes56 weeks3,7317.4% weight loss3% on placebo

Trial sources: SCALE Obesity and Prediabetes (FDA label (DailyMed)).

What is different for people with PCOS?

Details in the label for Saxenda and polycystic ovary syndrome (PCOS)
What changesWhat the label says
HypoglycemiaThe risk of low blood sugar goes up when it is used with insulin or a sulfonylurea, so you may need lower doses of them.

Source of the label details: FDA label on DailyMed.

Label warnings: FDA label on DailyMed.

Coverage for PCOS

If a GLP-1 is taken only for weight loss, Medicare Part D does not cover it.

Where Medicaid covers weight-loss GLP-1s, prior authorization is the usual rule.

Sources: humana.com, KFF.

Alternatives for PCOS

GLP-1 medicines and polycystic ovary syndrome (PCOS)
MedicineFor PCOSHow it is takenTrial result
SaxendaNot a listed usedaily injection7.4% weight loss
OzempicNot a listed useweekly injectionNot listed
WegovyNot a listed useweekly injection or daily tablet14.9% weight loss
RybelsusNot a listed usedaily tabletNot listed
MounjaroNot a listed useweekly injectionNot listed
ZepboundNot a listed useweekly injection20.9% weight loss
FoundayoNot a listed usedaily tablet11.1% weight loss
TrulicityNot a listed useweekly injectionNot listed
VictozaNot a listed usedaily injectionNot listed
ByettaNot a listed usetwice-daily injectionNot listed

Source: FDA label from DailyMed.

Questions to ask your prescriber

See the complete Saxenda prescribing information on DailyMed.